Brain drug developer Adamas loses ground in stock debut
April 10, 2014 at 19:20 PM EDT
Shares of brain drug developer Adamas Pharmaceuticals Inc. fell nearly 12.5 percent from its initial public offering Thursday as the broader market and biotech stocks slid...